ProCE Banner Activity

CAPTIVATE: 3-Yr Follow-up Analysis From the Fixed-Duration Cohort of First-line Ibrutinib + Venetoclax for CLL/SLL

Slideset Download
Conference Coverage
The 3-year update of the CAPTIVATE fixed-duration cohort continues to show deep and durable responses with first-line ibrutinib + venetoclax in CLL/SLL including in patients with high-risk features.

Released: June 10, 2022

Expiration: June 09, 2023

Share

Provided by

Provided by Clinical Care Options, LLC
ProCE Banner

Supporters

Supported by educational grants from

AbbVie

AstraZeneca

AstraZeneca

Bristol Myers Squibb

Daiichi Sankyo, Inc.

Gilead Sciences, Inc.

GlaxoSmithKline

Jazz Pharmaceuticals, Inc.

Merck Sharp & Dohme Corp.

Novartis Pharmaceuticals Corporation

Seagen

Seagen and Genmab